What is Cingulate?
Headquartered in Kansas City, Kansas, Cingulate operates at the intersection of pharmacology and patient-centric engineering. Since its inception in 2012, the company has focused on the development of its proprietary Precision Timed Release drug delivery platform. This technology is engineered to solve the persistent challenge of burdensome dosing schedules, which often lead to poor patient adherence and inconsistent therapeutic efficacy. By refining the delivery mechanism of established compounds, Cingulate aims to create a robust portfolio of pharmaceutical assets that offer superior clinical profiles compared to existing standard-of-care treatments. The company's market position is defined by its commitment to transforming the patient experience through precision-engineered therapeutic delivery.
How much funding has Cingulate raised?
Cingulate has raised a total of $26.3M across 6 funding rounds:
Private Equity
$6.8M
Private Equity
$7.5M
Debt
$150K
Debt
$237K
Share Placement
$5M
Debt
$6.6M
Private Equity (2013): $6.8M, investors not publicly disclosed
Private Equity (2018): $7.5M led by Werth Family Investment Associates
Debt (2020): $150K supported by PPP
Debt (2021): $237K featuring PPP
Share Placement (2024): $5M, investors not publicly disclosed
Debt (2025): $6.6M, investors not publicly disclosed
Key Investors in Cingulate
Werth Family Investment Associates
A private investment firm focused on long-term capital appreciation and strategic support for growth-oriented enterprises.
PPP
Public-Private Partnership
Undisclosed Investor
An undisclosed participant providing strategic backing to support the advancement of clinical-stage pharmaceutical development.
What's next for Cingulate?
With the successful closure of this major strategic investment, Cingulate is poised to accelerate its clinical trial milestones and regulatory submission timelines. The strategic deployment of these funds will likely prioritize the expansion of its core pipeline, ensuring that the Precision Timed Release platform reaches commercial viability. Investors and industry analysts will be closely monitoring the company's ability to translate this capital into tangible clinical data, particularly as it seeks to disrupt the market for frequently diagnosed conditions. The focus remains on achieving key regulatory benchmarks that will validate the platform's efficacy and pave the way for future commercialization efforts in the highly competitive biopharmaceutical landscape.
See full Cingulate company page
